Abstract
Melanoma is curable when detected early, with 5-year survival ranging from 93% to 100% when Breslow thickness at the time of excision is less than 0.76mm [1]. Prognosis worsens with increasing thickness, though, and even with advances in melanoma awareness many melanomas are detected too late: 5-year mortality from localized melanoma (American Joint Committee on Cancer Stages I and II) ranges from 15% to 35% in different centers [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Balch CM, Cascinelli N, Drzewiecki KT, Eldh G, MacKie RM, McCarthy WH, et al. 1992. A comparison of prognostic figures worldwide. In CM Balch, AN Houghton, GW Milton, AJ Sober, S Soong (eds), Cutaneous Melanoma, 2nd ed. Philadelphia: JB Lippincott, p. 194.
Fitzpatrick TB, Milton GW, Balch CM, Shaw HM, McCarthy WH, Sober AJ. 1992. Clinical characteristics. In CM Balch, AN Houghton, GW Milton, AJ Sober, S Soong (eds), Cutaneous Melanoma, 2nd ed. Philadelphia: JB Lippincott, pp 229–230.
Friedman RJ, Rigel DS. 1985. The clinical features of malignant melanoma. Dermatol Clin 3:271–283.
McGovern TW, Litaker MS. 1991. Clinical predictors of malignant pigmented lesions. A comparison of the Glasgow seven-point checklist and the American Cancer Society’s ABCDs of pigmented lesions. J Dermatol Surg Oncol. 18:22–26.
Koh HK. 1991. Cutaneous melanoma. N Engl J Med 325:171–182.
Ho VC, Milton GW, Sober AJ. 1992. Biopsy of melanoma. In CM Balch, AN Houghton, GW Milton, AJ Sober, S Soong (eds), Cutaneous Melanoma, 2nd ed. Philadelphia: JB Lippincott, pp 265–268.
Andersen WK, Silvers DN. 1991. Melanoma? It can’t be melanoma! A subset of melanomas that defies clinical recognition. JAMA 266:3463–3465.
Grossman DJ. 1989. Public and professional educational materials on skin cancer. J Am Acad Dermatol 21:1012–1018.
Hennrikus D, Girgis A, Redman S, Sanson-Fisher RW. 1991. A community study of delay in presenting with signs of melanoma to medical practitioners. Arch Dermatol 127:356–361.
Koh HK, Lew RA, Prout MN. 1989. Screening for melanoma/skin cancer: Theoretic and practical considerations. J Am Acad Dermatol 20:159–172.
Koh HK, Caruso A, Gage I, Geller AC, Prout MN, White H, O’Connor K, Balash EM, Blumenthal G, Rex IH JR, et al. 1990. Evaluation of melanoma/skin cancer screening in Massachusetts. Preliminary results. Cancer 15:375–379.
Koh HK, Geller AC, Miller DM, Caruso A, Gage I, Lew RA. 1991. Who is being screened for melanoma/skin cancer? Characteristics of persons screened in Massachusetts. J Am Acad Dermatol 24:271–277.
Lee G, Massa MC, Welykyj S, Choo J, Greaney V. 1991. Yield from total skin examination and effectiveness of skin cancer awareness program. Findings in 874 new dermatology patients. Cancer 67:202–205.
Lookingbill DP. 1988. Yield from a complete skin examination: Findings in 1157 new dermatology patients. J Am Acad Dermatol 18:31–37.
Rhodes AR, Weinstock MA, Fitzpatrick TB, Mihm MC Jr, Sober AJ. 1987. Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA 258:3146–3154.
MacKie RM, Freudenberger T, Aitchison TC. 1989. Personal risk-factor chart for cutaneous melanoma. Lancet 2:487–490.
Cohen MH, Cohen BJ, Shotkin JD, Morrision PT. 1991. Surgical prophylaxis of malignant melanoma. Ann Surg 213:308–314.
Kraemer KH, Greene MH, Tarone R, Elder DE, Clark WH Jr, Guerry D 4th. 1983. Dysplastic nevi and cutaneous melanoma risk (letter). Lancet 2:1076–1077.
Barnes LM, Nordlund JJ. 1987. The natural history of dysplastic nevi. A case history illustrating their evolution. Arch Dermatol 123:1059–1061.
Bergman W, Palan A, Went LN. 1986. Clinical and genetic studies in six Dutch kindreds with the dysplastic nevus syndrome. Ann Hum Genet 50:249–258.
Bale SJ, Chakravarti A, Greene MH. 1986. Cutaneous malignant melanoma and familial dyspastic nevi: Evidence for autosomal dominance and pleiotropy. Am J Hum Genet 38:188–196.
Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. 1985. High risk of malignant melanoma in melanoma-prone patients with dysplastic nevi. Ann Intern Med 102:458–465.
Halpern AC, Guerry D 4th, Elder DE, Clark WH Jr, Synnestvedt M, Norman S, Ayerle R. 1991. Dysplastic nevi as risk factors of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol 127:995–999.
Geller AC, Koh HK, Miller DR, Lew RA. 1992. Practices and beliefs concerning screening family members of patients with melanoma. Results of a survey of New England dermatologists. J Am Acad Dermatol 26:419–422.
Crijns MB, Vink J, Van Hees CL, Bergman W, Vermeer BJ. 1991. Dysplastic nevi. Occurrence in first-and second-degree relatives of patients with’ sporadic’ dysplastic nevus syndrome. Arch Dermatol 127:1346–1351.
Albert LS, Rhodes AR, Sober AJ. 1990. Dysplastic melanocytic nevi and cutaneous melanoma: Markers of increased melanoma risk for affected persons and blood relatives. J Am Acad Dermatol 22:69–75.
Tiesten AD, Grin CM, Kopf AW, Gottlieb GJ, Bart RS, Rigel DS, Friedman RJ, Levenstein MJ. 1991. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. J Dermatol Surg Oncol 17:44–48.
Masri GD, Clark WH Jr, Guerry D 4th, Halpern A, Thompson CJ, Elder DE. 1990. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 22:1042–1048.
Vasen HFA, Bergman W, Van Haeringen A, Scheffer E, Van Slooten EA. 1989. The familial dysplastic nevus syndrome. Natural history and the impact of screening on prognosis. A study of nine families in the Netherlands. Eur J Cancer Clin Oncol 25:337–341.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Albert, L.S., Sober, A.J. (1993). Early detection of melanoma. In: Nathanson, L. (eds) Current Research and Clinical Management of Melanoma. Cancer Treatment and Research, vol 65. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3080-0_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3080-0_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6345-3
Online ISBN: 978-1-4615-3080-0
eBook Packages: Springer Book Archive